IP Verse

Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect

PatentPatent Analysis

EP3368071

REVANCE THERAPEUTICS
Application Number
EP16860952A
Filing Date
Oct 28, 2016
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2490986B2
EP2661276B1

Bibliography

The patent EP3368071B1 was granted to Revance Therapeutics on Jan 26, 2022 following the initial filing on Oct 28, 2016 under the application number EP16860952A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

IPSEN BIOPHARMAOct 26, 2022ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents